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Phe Extent of Perfusion–F18-Fluorodeoxyglucose
ositron Emission Tomography Mismatch
etermines Mortality in Medically Treated Patients
ith Chronic Ischemic Left Ventricular Dysfunction
lessandro Desideri, MD, FACC,* Lauro Cortigiani, MD,* Alejandra Ines Christen, MD,*
ebastian Coscarelli, MD,* Dario Gregori, PHD,† Pierluigi Zanco, MD,‡ Roman Komorovsky, MD,*
eroen J. Bax, MD§
astelfranco and Torino, Italy; and Leiden, the Netherlands
OBJECTIVES The purpose of this study was to assess the determinants of mortality in a large group of
patients with ischemic cardiomyopathy who are treated medically and the impact of the extent
of viable tissue on prognosis.
BACKGROUND Whether the presence of viability drives mortality in patients with ischemic cardiomyopathy
who are treated medically and whether the extent of viability is important are issues that are
currently unclear.
METHODS Two hundred sixty-one patients with ischemic cardiomyopathy underwent positron emission
tomography (PET) for assessment of viability. Prospective follow-up was obtained.
RESULTS Ninety-four patients were revascularized and 167 were not. The cardiac death rate was
significantly less in the revascularized patients as compared with medically treated patients
(13% vs. 24%, p  0.05). In the revascularized patients, there was a trend toward better
survival in patients with viable myocardium as compared with nonviable myocardium
(3.5-year survival, 85% and 75% respectively, p  NS). In the medically treated group, age
(hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.2 to 3.7), presence of left bundle
branch block (HR 3.4, 95% CI 1.6 to 7.2) and extent of perfusion-metabolism mismatch on
PET (HR 1.36, 95% CI 1.1 to 1.6) predicted cardiac death during a median follow-up period
of 2.1 years. The risk of cardiac death was not significantly increased when the extent of
mismatch was 20% (HR 0.97, 95% CI 0.46 to 2.05) but was significantly increased when
the extent of mismatch was 20% (HR 3.21, 95% CI 1.38 to 7.49).
CONCLUSIONS Medically treated patients with ischemic cardiomyopathy and large areas of viable myocar-
dium on PET are at high risk for cardiac death. (J Am Coll Cardiol 2005;46:1264–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.057© 2005 by the American College of Cardiology Foundation
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piability assessment is important for management of pa-
ients with ischemic cardiomyopathy. Patients with viable
yocardium who undergo revascularization improve in
unction and have a favorable prognosis (1–4). Pooling of
ve prognostic F18-fluorodeoxyglucose (FDG) positron
mission tomography (PET) studies with 662 patients
howed an event rate of 7% in 178 patients with viable
yocardium who underwent revascularization (5).
In sharp contrast, patients with viable myocardium who
re medically treated seemed to have a high event rate and
oor prognosis. In the five pooled FDG PET studies, a 20%
vent rate was reported in 75 patients with viable myocar-
ium who were treated medically. It has been hypothesized
hat residual viable myocardium should be considered as an
nstable substrate and that medical treatment of these
atients results in a high event rate. Whether the viability or
From the *Cardiovascular Research Foundation, “S. Giacomo” Hospital, Castel-
ranco Veneto, Italy; †Department of Public Health and Microbiology, University of
orino, Torino, Italy; ‡PET Center, Nuclear Medicine Department, “S. Giacomo”
ospital, Castelfranco Veneto, Italy; and the §Department of Cardiology, Leiden
niversity Medical Center, Leiden, the Netherlands. The study was supported by the
ardiovascular Research Foundation research fellowship program.v
Manuscript received February 28, 2005; revised manuscript received June 7, 2005,
ccepted June 13, 2005.ther factors drive the high event rate is still unclear. In
ddition, whether the simple presence of viable myocar-
ium, or rather, the extent of viable tissue is important for
ong-term prognosis in medically treated patients is also
nclear. Accordingly, the aim of the present study was to
valuate which parameters determine the long-term prog-
osis in patients with ischemic cardiomyopathy who are
edically treated, and furthermore, to verify whether small
reas of viability might already cause an increase in the risk
f death in medically treated patients or that only patients
ith large areas of viability are at increased risk of death.
ETHODS
tudy population. A total of 261 patients were clinically
eferred for assessment of viability by PET; these patients
ad chronic coronary artery disease (CAD) on angiography
ith depressed left ventricular (LV) function, as defined by
LV ejection fraction (EF) 40%, and underwent evalua-
ion for surgical revascularization. Criteria for revasculariza-
ion were feasible anatomy, no extensive co-morbidity and
nformed consent of the patient. Of this population, 167
atients were not revascularized on the basis of poor target
essels (n  143), extensive co-morbidity (n  15), or
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October 4, 2005:1264–9 PET Mismatch and Prognosisatient refusal for revascularization (n  9). These patients
ere prospectively followed-up and represent the study
opulation.
ET. The PET studies were performed with an ECAT
XACT (CTI, Knoxville, Tennessee) scanner, which allows
imultaneous acquisition of 47 contiguous transaxial images,
ith a total axial field of view of 16.2 cm. The resolution of the
canner was 4.8  0108 0.6 mm in the axial direction and
.1  0108 0.2 mm in the transaxial planes. A transmission
can was obtained for 15 min to allow for attenuation
orrection with retractable germanium-68 ring sources. For
mission studies, the tracers used were N-13 ammonia
NH3) (10 MBq/kg) to assess resting perfusion and FDG
4 MBq/kg) to assess glucose use; FDG was injected 45 min
fter oral glucose loading (50 g). The emission scans were
tarted 4 min after injection of NH3 and 45 min after FDG
njection. Data acquisition lasted 15 min for both tracers.
hort-axis and vertical and horizontal long-axis slices
thickness 0.8 cm each) were reconstructed with a Hanning
lter (cut-off 1.18 cycle/cm) and corrected for attenuation.
oth studies were performed on the same day in all of the
atients: first, the N13-ammonia study, followed by the
DG study 2 h later.
For image evaluation, a semi-quantitative analysis was
erformed, dividing the LV into 16 segments. After nor-
alization to the maximum counts in the myocardium, the
elative percentage of NH3- and FDG-uptake was then
alculated in regions of interest (8 8 mm-sized), drawn in
he center of each segment.
Segments with reduced perfusion (tracer uptake70% of
aximum) and relatively preserved FDG uptake (tracer
ptake 70%) were considered viable (perfusion-FDG
ismatch). Segments with reduced perfusion and concor-
antly reduced FDG uptake (both tracers uptake 70% of
aximum, perfusion-FDG match) were considered nonvi-
ble (6). The presence of a perfusion-FDG mismatch in1
egment was used to classify patients as having viable tissue.
he extent of the viable area was calculated as the percent-
ge of the LV with a mismatch pattern and the extent of the
onviable area was calculated as the percentage of the LV
ith a match pattern. All studies were analyzed by three
xperienced observers, and a majority decision was achieved.
ong-term follow-up. Long-term follow-up was obtained
rom patient interviews at the outpatient clinic, hospital
Abbreviations and Acronyms
CABG coronary artery bypass graft
CAD  coronary artery disease
EF  ejection fraction
FDG  F18-fluorodeoxyglucose
LBBB  left bundle branch block
LV  left ventricle/ventricular
MI  myocardial infarction
PET  positron emission tomographyhart reviews, and telephone interviews with the patient, plose relative, or referring physician. Only cardiac death was
aken into account as event. Death was defined as cardiac if
trictly related to proven cardiac causes (i.e., fatal reinfarc-
ion, refractory heart failure, or ventricular arrhythmias).
tatistical analysis. Continuous variables are presented as
edian values, and categorical variables are presented as
ercentages. Survival curves were estimated and plotted on
he basis of the Kaplan-Meier estimator. The individual
ffect of clinical (age, gender, hypertension, dyslipidemia,
moking, diabetes, history of infarction, previous revascu-
arization procedures, left bundle branch block [LBBB] on
lectrocardiogram [ECG]), angiographic (three-vessel dis-
ase, LVEF), and PET data (presence/absence of viability,
xtent of the viable area, and extent of the nonviable area)
n survival was evaluated by Cox proportional-hazards
egression analysis. First, univariate hazard ratios (HRs) for
ach of the observed covariate were computed along with
heir 95% confidence intervals (CIs). Then, a multivariate
ox proportional hazard model was selected. All variables
onsidered were entered into the model “as is” (i.e., without
ny transformation or cutting-off). Selection criteria was the
kaike Information Criterion (AIC) applied backward for
ach model tested. The final model was selected if superior
n terms of AIC at a significance level of 0.05. Proportion-
lity in hazard was carefully checked, both with visual
nalysis of Schoenfeld residuals and, formally, with the
rambsch-Therneau test. Thus, for the final model, mul-
ivariate HRs have been presented along with their 95%
Is. Finally, effect of mismatch on survival was modeled
ith a non-linear restricted cubic spline function, tested. All
omputations were performed with S-plus version 2000 and
he Harrell’s Design and Hmisc libraries (Insightful Corp.,
eattle, Washington) (7). Somer’s discrimination index (8)
as used to evaluate goodness of fit. For all tests, a p value
0.05 was considered significant.
ESULTS
aseline characteristics of medically treated and revascular-
zed patients were comparable (Table 1).
The 167 patients who did not undergo revascularization
nd were medically treated represent our study population.
linical characteristics of the study population, combined
nd stratified according to the occurrence of a mismatch
attern, are reported in Table 2. In 107 patients, no
ismatch pattern was present on PET imaging, whereas 60
atients showed at least one segment with a mismatch
attern. Patients with a mismatch pattern did not differ in
ge, gender, previous myocardial infarction and/or previous
evascularization procedures, and presence of LBBB on
CG from patients without a mismatch pattern. The
revalence of risk factors and co-morbidity was similar in
he two groups. On the basis of the inclusion criteria, all
atients had significant CAD on coronary angiography. In
articular, three-vessel disease was present in 79 (47%)
atients and was observed in 36 of 60 patients with a
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PET Mismatch and Prognosis October 4, 2005:1264–9ismatch (60%) and in 43 of 107 patients without a
ismatch (33%) (p  0.05). Median LVEF was 29% (first
uartile, 22%; third quartile, 34%), with no difference
etween patients with and without mismatch.
The prescribed medical treatment was as follows:
ngiotensin-converting enzyme inhibitors were used in 93%
f patients, diuretics in 72%, aspirin and/or oral anti-
oagulation in 93%, nitrates in 60%, beta-blockers in 41%,
alcium antagonists in 15%, digoxin in 41%, and amioda-
one in 21% of patients.
rediction of long-term outcome. During a median
ollow-up period of 2.1 years (first to third quartile, one to
hree years), a total of 40 cardiac deaths occurred in the
tudy population (Fig. 1).
Table 1. Clinical Characteristics of Medically T
Medically Tre
(n 
Age (yrs) 66 [5
Male 89%
Hypertension 50%
Diabetes 10%
Dyslipidemia 50%
Smoking 52%
Family history of CAD 31%
NYHA functional class III to IV 62%
Previous MI 82%
Previous PTCA 5%
Previous CABG 6%
Presence of LBBB 22%
Peripheral vascular disease 4%
Severe COPD 5%
Renal failure 6%
LVEF (%) 29 [2
PET MM present 36%
Extent of MM (%) 13 [7
*Continuous variables are presented as median (first and t
percentages (absolute number in parentheses).
CABG  coronary artery bypass grafting; CAD  corona
LBBB  left bundle branch block; LVEF  left ventricular
NYHA  New York Heart Association; PET  position em
angioplasty.
able 2. Clinical Characteristics of the Medically Treated Study
Medically Treated Patients
(n  167)
Pa
ge (yrs) 66 [57, 69]
ale 89% (148)
ypertension 50% (83)
iabetes 10% (16)
yslipidemia 50% (83)
moking 52% (87)
amily history of CAD 31% (51)
revious MI 82% (137)
revious PTCA 5% (9)
revious CABG 6% (10)
resence of LBBB 22% (37)
eripheral vascular disease 4% (7)
evere COPD 5% (8)
enal failure 6% (10)
VEF (%) 29 [22, 34]Continuous variables are presented as median (first and third quartile in brackets). Catego
Abbreviations as in Table 1.Univariable predictors of cardiac death were age, diabetes,
moking, previous myocardial infarction, presence of
BBB, three-vessel disease on angiography, and extent of a
ismatch pattern on PET imaging. The simple presence of
mismatch pattern was not predictive of death (Table 3).
car tissue (match pattern) involved a median of 30% of the
eft ventricle (first to third quartile, 18% to 42%) and was
ot a predictor of cardiac death during follow-up.
Multivariable analysis selected age (p 0.005), LBBB (p
.001), and extent of mismatch on PET imaging (p  0.001)
s independent prognostic indicators (Table 3). The extent
f mismatch was strongly related (HR 1.36, 95% CI 1.13 to
.64) to mortality, with an 8% increase in extent of
ismatch determining a 36% increase in risk of cardiac
ed and Revascularized Patients*
Patients Revascularized Patients
(n  94) p Value
66 [58, 70] NS
89% (84) NS
50% (47) NS
12% (11) NS
65% (61) NS
75% (70) NS
41% (38) NS
65% (61) NS
79% (74) NS
8% (8) NS
6% (6) NS
17% (16) NS
9% (8) NS
5% (5) NS
8% (8) NS
30 [25, 35] NS
58% (55) 0.001
20 [10, 30] 0.001
uartile in brackets). Categorical variables are presented as
ry disease; COPD  chronic obstructive pulmonary disease;
n fraction; MI  myocardial infarction; MM  mismatch;
tomography; PTCA  percutaneous transluminal coronary
lation*
s Without Mismatch
(n  107)
Patients With Mismatch
(n  60) p Value
65 [55, 69] 67 [60, 71] NS
89% (95) 88% (53) NS
51% (55) 47% (28) NS
7% (7) 15% (9) NS
51% (55) 47% (28) NS
51% (55) 53% (32) NS
30% (32) 32% (19) NS
82% (88) 82% (49) NS
5% (5) 7% (4) NS
6% (6) 7% (4) NS
22% (24) 22% (13) NS
5% (5) 3% (2) NS
5% (5) 5% (3) NS
6% (6) 7% (4) NS
28 [22, 34] 29 [23, 34] NSreat
ated
167)
7, 69]
(148)
(83)
(16)
(83)
(87)
(51)
(104)
(137)
(9)
(10)
(37)
(7)
(8)
(10)
2, 34]
(60)
, 20]
hird q
ry arte
ejectioPopu
tientrical variables are presented as percentages (absolute number in parentheses).
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October 4, 2005:1264–9 PET Mismatch and Prognosiseath during follow-up (Table 3, Fig. 2). To describe the
elation between extent of mismatch and mortality, a plot of
og-hazard versus mismatch in non-linear terms is shown in
igure 2. The risk of cardiac death is not significantly
ncreased when the extent of mismatch is 20% (HR 0.97,
5% CI 0.46 to 2.05), but the risk of death is significantly
ncreased when the extent of mismatch exceeds 20% (HR
.21, 95% CI 1.38 to 7.49).
igure 1. Kaplan-Meier survival curve with 95% confidence intervals in
ime-intervals is indicated.
able 3. Univariable and Multivariable Analysis*
No Event
(n  127)
Event
(n  40) HR
ge (yrs) 64 [55, 69] 68 [61, 72] 2.0
ale 90% (114) 85% (34) 1.2
ypertension 45% (56) 25% (10) 0.5
iabetes 7% (9) 18% (7) 2.8
yslipidemia 58% (74) 22% (9) 0.2
moking 38% (48) 80% (32) 5.8
revious MI 13% (17) 32% (13) 2.2
revious PTCA 6% (8) 2% (1) 0.5
revious CABG 6% (7) 8% (3) 1.1
resence of LBBB 17% (21) 40% (16) 2.0
VEF (%) 29 [22, 34] 27 [25, 30] 0.8
-vessel disease 37% (47) 55% (22) 2.4
ET MM present 34% (43) 42% (17) 1.4
xtent of MM (%) 10 [7, 20] 15 [7, 30] 1.2
xtent of scar (%) 30 [18, 42] 30 [18, 30] 1.0
Study population (n  167), stratified according the occurrence of cardiac death. Co
ariables are presented as percentages (absolute number in parentheses). Univariable
odel for hard events: HR for LBBB and extent of mismatch (MM) have been compu
 0.0047) at 0. After 500 bootstrap replications, Somer’s discrimination index was estim
Abbreviations as in Table 1.For comparison, in the 94 revascularized patients, 12
13%) cardiac deaths occurred during follow-up. The car-
iac death rate was significantly less in the revascularized
atients as compared with the medically treated patients
13% vs. 24%, p  0.05). In particular, the cardiac death
ate was significantly higher in viable patients who were
reated medically as compared with viable patients who
nderwent revascularization (28% vs. 15%, p 0.05). In the
edically treated patients; the number of patients at risk at the different
ivariable Analysis Multivariable Analysis
95% CI p Value HR 95% CI p Value
1.2–3.4 0.005 2.1 1.2–3.7 0.005
0.5–2.8 NS
0.2–0.9 0.03
0.9–4.7 0.08
0.1–0.4 0.001
2.7–12.6 0.001
1.1–4.2 0.02
0.1–3.3 NS
0.3–3.7 NS
1.1–3.9 0.03 3.4 1.6–7.2 0.001
0.5–1.4 NS
1.3–4.4 0.04
0.7–2.6 0.07
1–1.36 0.05 1.36 1.1–1.6 0.001
0.51–2.0 NS
us variables are presented as median (first and third quartile in brackets). Categorical
ratios (HR) are presented with their 95% confidence intervals (CI). Multivariable
justing the respective values in the interaction term (coefficient0.083, SEM 0.0294,Un
ntinuo
hazard
ted, ad
ated as Dxy  0.35.
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PET Mismatch and Prognosis October 4, 2005:1264–9evascularized patients, there was a trend toward better
urvival in patients with viable myocardium as compared
ith nonviable myocardium (3.5-year survival, 85% and
5%, respectively, p  NS).
ISCUSSION
t has been postulated that the presence of viable myocar-
ium represents an unstable situation, prone to ischemic
nd arrhythmic events in patients who do not undergo
evascularization; on the basis of this hypothesis, the extent
f jeopardized, viable myocardium might be of less impor-
ance than the simple presence of viable tissue. The results
f the current study, however, indicate that not simply the
resence of a perfusion-FDG mismatch but rather the
xtent of mismatch determines the long-term mortality in
atients with ischemic cardiomyopathy who are medically
reated.
The identification of residual viability is a key element for
ptimal management of patients with ischemic cardiomy-
pathy, who represent a high-risk population that, even
hen revascularized, showed a 13% death rate during
ollow-up in our series. In patients with a LVEF35%, the
erioperative and in-hospital mortality are lower and one-
ear survival is better when the need for revascularization is
uided by pre-operative assessment of viability (9). Con-
ersely, patients with viable myocardium who do not un-
ergo revascularization seem to have poor outcome. Pooling
f the five available prognostic studies with FDG PET
10–14) revealed a mean death rate of 17% (ranging from
% to 33%) in 75 medically treated patients who had viable
issue on FDG PET. The main shortcoming of these
revious reports lies in the retrospective, non-randomized
haracter of the studies and the limited number of patients
er study. In addition, the reasons why patients with viable
yocardium did not undergo revascularization are not clear
igure 2. Plot of log-hazard versus mismatch (MM) in non-linear terms.
he graph indicates a non-significant effect on risk of having a mismatch
ith an extent 20% compared with 0% (hazard ratio [HR] 0.97, 95%
onfidence interval [CI] 0.46 to 2.05), whereas the effect is significant when
he extent of mismatch exceeds 20% (HR 3.21, 95% CI 1.38 to 7.49).rom the studies, and it has been suggested that the high rvent rate might not be due to viability (progressing to scar
issue) but rather due to the presence of excessive co-
orbidity (which might also be the reason why the patients
id not undergo revascularization).
The issue of what drives mortality in the medically
reated patients is an important one and was the topic of the
urrent study. Forty of 167 medically treated patients died
uring the median follow-up of 2.1 years, resulting in a
omparably high mortality rate (21% per year), as reported
n the previous studies. Univariable analysis identified many
ariables associated with a higher event rate (Table 2), but
nly age, the presence of LBBB on the ECG, and the extent
f mismatch on PET were the variables that remained
redictive on multivariable analysis. These observations
uggest that co-morbidity does not primarily drive mortality
n patients with ischemic cardiomyopathy but, indeed, it is
he extent of viable myocardium that does so. In fact, small
reas (20%) of viable myocardium did not affect prognosis
ignificantly, but when the mismatch area exceeded 20% of
he myocardium, a steep increase in mortality was observed
Fig. 2). The previous studies did not specifically focus on
he extent of viable myocardium that was associated with an
ncreased event rate; these previous studies only showed the
ncreased event rate in the viable, medically treated patients.
i Carli et al. (12) showed that patients with 5% viability of
he left ventricle already had a high event rate when
edically treated. Still, the mean extent of viability in the
edically treated patients was 17  15%, and also, that
tudy was not specifically designed to address what extent of
iability is associated with a high event rate.
None of the traditional clinical data (e.g., previous in-
arction, LVEF, three-vessel disease) remained predictive in
he multivariable analysis; this finding is probably related to
he fact that the majority of patients in the current study had
everely depressed LVEF, frequently secondary to previous
nfarction, and extensive three-vessel CAD. Moreover, our
esults confirm previous observations that patients with
AD and concomitant LBBB have increased cardiovascular
ortality as compared with patients without LBBB (15).
eft bundle branch block is a commonly observed ventric-
lar conduction disturbance occurring in patients with
educed LV function, and it might adversely affect prognosis
n different manners. Experimentally induced LBBB causes
tructural changes such as eccentric hypertrophy and deter-
ines unequal synthesis of stress kinases and calcium-
andling proteins (16,17). Also, asynchrony in ventricular
ctivation and pressure generation might result in ineffective
V ejection, reduced LV filling time, and worsening of
itral regurgitation (18).
Another important observation in our study was that the
xtent of scar tissue was not predictive of death. Beanlands
t al. (19) demonstrated recently that, besides viability, the
xtent of scar tissue was an independent predictor of
mprovement in LVEF after revascularization. Patients with
iability demonstrated improvement in LVEF post-
evascularization, but the improvement in LVEF was neg-
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October 4, 2005:1264–9 PET Mismatch and Prognosistively affected by the presence of extensive scar tissue. In
hat study, however, no survival data were presented. In the
urrent study, it was demonstrated that the extent of scar
issue did not negatively affect survival, but this observation
ight be due to the fact that the majority of patients had
xtensive scar tissue.
It should be mentioned that only 41% of the patients used
eta-blockers, the same percentage as receiving digoxin.
ith changing insight in medical therapy, the current
ercentage of patients with ischemic cardiomyopathy using
eta-blockers is expected to be higher.
tudy limitations. The same limitation as with all prog-
ostic viability studies applies to the current study: it is
on-randomized study, although the patients were prospec-
ively followed-up. A difference in time period since the
ndex MI in patients with and without mismatch was not
rospectively assessed.
onclusions. Positron emission tomography remains a
owerful tool for risk stratification of patients with ischemic
ardiomyopathy who do not undergo surgical revasculariza-
ion. Patients with large areas (20% of the LV) of viable
yocardium on PET imaging have a high mortality during
ollow-up. It is not any viability but, rather, extensive
iability that determines prognosis in patients with ischemic
ardiomyopathy who are medically treated.
eprint requests and correspondence: Dr. Alessandro Desideri,
ardiovascular Research Foundation, S. Giacomo Hospital, 31033
astelfranco Veneto (TV), Italy. E-mail: aldesi@tin.it.
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